ReviewNature reviews. Immunology2026
Interleukin-33 and its receptor: multifaceted roles and emerging therapeutic potential.
Review in Nature reviews. Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-33 (IL-33) is an alarmin and cytokine that has potent biological effects in various tissues. It acts on a broad array of immune cell populations and is involved in many processes associated with health and disease. This Review discusses the biology of IL-33 and its receptor, ST2, and the functional relevance of IL-33-ST2 signalling. It focuses particularly on the differential regulation of IL-33 sensitivity in distinct cell types in diverse tissue settings. Furthermore, we describe the effects of IL-33 in various diseases, including viral infections, cancer, graft-versus-host disease, colitis, autoimmunity, chronic obstructive pulmonary disease, asthma and allergy. We also consider the roles of IL-33 in physiological reactions such as fat tissue biology and tissue regeneration. The Review aims to provide a comprehensive understanding of IL-33 signalling, including its potential as a target for developing new treatments, and to suggest future research directions.
Identifiers
42686822What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.